Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Matrices
Reexamination Certificate
2007-03-13
2007-03-13
Webman, Edward J. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Matrices
C424S488000, C424S468000, C514S772600, C514S781000
Reexamination Certificate
active
10630917
ABSTRACT:
The invention relates to synchronous drug delivery composition comprising a polymeric matrix which comprises hydrogel blended with a hydrophobic polymer, so as to form an erodible matrix, a drug, and, optionally, an agent which enhances intestinal drug absorption and/or an agent which inhibits intestinal drug degradation,wherein erosion of the erodible matrix, permits synchronous release of the drug, the hydrogel and the intestinal drug absorption agent and/or the agent which inhibits intestinal drug degradation.
REFERENCES:
patent: 4568559 (1986-02-01), Nuwayser et al.
patent: 5160737 (1992-11-01), Friedman et al.
patent: 6692766 (2004-02-01), Rubinstein et al.
patent: 252539 (1987-12-01), None
Battaglia, E., et al., Characterization of a New Class of Inhibitors of the Recombinant Human Liver UDP-Glucuronosyltransferase, UGT1*6, Biochimica et Biophysica Acta, 1243 : 9-14 (1995).
Benet, L.Z., et al., “Importance of Drug Metabolism and Antitransport Processes: A Paradigm Shift in Oral Drug Delivery,” Proceedings of the 7th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, pp. 11-14 (1995).
Borchard, G., et al., “Multifunctional Polymers for Improved Peroral Peptide Drug Absorption,” Proceedings of the 7th International Symposium on Recent Advances in Drug Delivery Systems, Salt Lake City, Utah, pp. 7-10, Bai J. P-F., et al. ibit., pp. 153-154 (1995).
Chao, Y.W. and Flynn, M., “Oral Delivery of Insulin,” Lancet, 23 : 1518-1519 (1989).
Damge, C., et al., “New Approach for Oral Administration of Insulin with Polyalkylcyanoacrylate Nanocapsules as Drug Carrier,” Diabetes, 37 : 246-251 (1988).
Danforth, Jr., E. and Moore, R.O., “Intestinal Absorption of Insulin in the Rat,” Endocrinology, 65 : 118-123 (1959).
Dapergolas, G. and Gregoriadis, “Hypoglyaemic Effect of Liposome-Entrapped Insulin Administered Intragastrically into Rats,” Lancet, 2 : 824-827 (1976).
Eudragit® RL Data Sheet (Info RL-3/e). No date given.
Eudragit® RL/RS Standards Sheet (Info RL/RS-7/e). No date given.
Eudragit® RL/RS Technical Application Pamphlet (Info RL/RS-11/e). No date given.
Eudragit® RL/RS Technical Application Pamphlet (Info RL/RS-12/e). No date given.
Eudragit® RL and RS Application in the Production of Pharmaceutical Preparations Prospectus (Info RL/RS-1/e). No date given.
Fahr, A., “Cyclosporin Clinical Pharmacokinetics,” Clin. Pharmacokinet., 24(6) : 472-495 (1993).
Geary, R.S. and Schlameus, H.W., “Vancomycin and Insulin Used as Models for Oral Delivery of Peptides,” J. Controlled Release, 23 : 65-74 (1993).
Goriya, Y., et al., “Blood Glucose Control and Insulin Clearance in Unrestrained Diabetic Dogs Portally Infused with a Portable Insulin Delivery System,” Diabetologia, 19 : 452-457 (1980).
Hochman, J.H., et al., “In vitro and In Vivo Analysis of the Mechanism of Absorption Enhancement by Palmitoylcamitine,” J. Parm. and Exp. Therap., 269 (2) : 813-822 (1994).
Hochman, J. and Artursson, P., “Mechanisms of Absorption Enhancement and Tight Junction Regulation,” J. Controlled Release, 29 : 256-267 (1994).
Honesch, H., et al., “Cytochrome P-450 and Drug Metabolism in Intestinal Villous and Crypt Cells of Rats: Effect of Dietary Iron,” Biochem and Biophys. Res. Comm., 65(1) : 399-406 (1975).
Kidron, M., et al., “The Absorption of Insulin From Various Regions of the Rat Intestine,” Life Science, 31 (25) : 2837-2841 (1982).
Kraeling, M.E.K. and Ritschel, W.A., “Development of a Colonic Release Capsule Dosage Form and the Absorption of Insulin,” Meth Find Exp. Clin. Pharmacol., 14(3) : 199-209 (1992).
Lee, V.H.L., et al., “Oral Route of Peptide and Protein Drug Delivery,” V.H.L. Lee (Ed.) : Peptide and Protein Drug Delivery, Marcel Dkker, 1991 New York, pp. 691-738.
Morishita, M., et al., “Novel Oral Microspheres of Insulin With Protease Inhibitor Protecting From Enzymatic Degradation,” Intl. J. Pharmaceutics, 78 : 1-7 (1992).
Muranishi, S., “Absorption Enhancers,” Critical Reviews in Therapeutic Drug Carrier Systems, 7(1) : 1-34 (1990).
Osborne, R., et al., “Morphine and Metabolite Behavior After Different Routes of Morphine Administration: Demonstration of the Importance of the Active Metabolite Morphine-6-Glucuronide,” Clin. Pharmacol, Ther., 47(1) : 12-19 (1990).
Patel, H.M. and Ryman, B.E., “Oral Administration of Insulin by Encapsulation Within Liposomes,” FEBS Letters, 26(1) : 60-63 (1976).
Peters, W.H.M., et al., “Glutathione S-Transferase, Cytochrome P450, and Uridine 5′—Diphosphate-Glucuronosyltransferase in Human Small Intestine and Liver,” Gastroenterology, 96 : 783-789 (1989).
Saffran, M., et al., “A New Approach to the Oral Administration of Insulin and other Peptide Drugs,” Science, 233 : 1081-1084 (1986).
Sanders, L.M., et al., “Prolonged Controlled-Release of Nafarelin, A Luteinizing Hormone-Releasing Hormone Analogue, From Biodegradable Polymeric Implants: Influence of Composition and Molecular Weight of Polymer,” J. Pharm. Sci., 75(4) : 356-360 (1986).
Sanders, L.M., et al., “Controlled Delivery of an LHRH Analogue From Bjodegradable Injectable Microspheres,” J. Controlled Release, 2 : 187-195 (1985).
Schulte-Hermann, R. and Parzefall, W., “Adaptive Responses of Ra Liver to the Gestagen and Anti-Androgen Cyproterone Acetate and other Inducers. I. Induction of Drug-Metabolizing Enzymes,” Chem Biol. Interactions, 31 : 279-286 (1980).
Takahashi, K., et al., “Decanoic Acid Induced Enhancement of Rectal Absorption of Hydrophilic Compounds in Rats,” Pharmaceutical Res., 11(10) : 1401-1404 (1994).
Takahashi, K., et al., “Pharmacokinetics Analysis of the Absorption Enhancing Action of Decanoic Acid and its Derivatives in Rats,” Pharm. Res., 11(3) : 388-392 (1994).
Touitou, E. and Rubinstein, A., “Targeted Enteral Delivery of Insulin to Rate,” Intl. J. Pharm., 30 : 95-99 (1986).
Van Hoogdalem, E.J., et al., “Intestinal Drug Absorption Enhancement: an Overview,” Pharmac, Ther., 44 : 407-443 (1989).
Wahlström, A., et al., “Tricyclic Antidepressants Inhibit Opioid.. Receptor Binding in Human Brain and Hepatic Morphine Glucuronidation,” Phar. & Toxic., 75 : 23-27 (1994).
Weingarten, C., et al., “Oral Ingestion of Insulin Liposomes: Effects on the Administration Route,” Life Science, 28 : 2747-2752 (1981).
Ziv, W., et al., Absorption of Protein via the Intestinal Wall, Bochem. Pharmcol, 36(7) : 1035-1039 (1987).
Database WPI, Week 9530, Derwent Publications Ltd., London, GB; AN 95-228636 & JP, A, 07 138 182 (Toyobo et al.), May 30, 1995 Abstract.
Baluom Muhammad
Friedman Michael
Rubinstein Abraham
Tirosh Boaz
Cohen Mark S.
Pearl Cohen Zedex Latzer, LLP
Webman Edward J.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Controlled release oral drug delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release oral drug delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release oral drug delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3728540